Colposcopy Referral and CIN3+Risk of Human Papillomavirus Genotyping Strategies in Cervical Cancer Screening

被引:2
作者
Kroon, Kelsi R. [1 ,2 ]
Bogaards, Johannes A. [1 ,2 ]
Heideman, Danielle A. M. [3 ,4 ,5 ]
Meijer, Chris J. L. M. [3 ,4 ]
Berkhof, Johannes [1 ,2 ]
机构
[1] Vrije Univ Amsterdam, Epidemiol & Data Sci, Amsterdam UMC, De Boelelaan 1089a, NL-1081 HV Amsterdam, Netherlands
[2] Amsterdam Publ Hlth Res Inst, Methodol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Pathol, Amsterdam UMC, Amsterdam, Netherlands
[4] Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands
基金
欧盟地平线“2020”;
关键词
RISK HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; BASE-LINE; CYTOLOGY; WOMEN; IMPLEMENTATION; GUIDELINES; POBASCAM;
D O I
10.1158/1055-9965.EPI-24-0046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: High-risk human papillomavirus (hrHPV)-based cervical cancer screening in the Netherlands led to a substantial increase in number of colposcopy referrals and low-grade lesions detected. Genotyping strategies may be employed to lower the screening-related burden.Methods: We evaluated 14 triage strategies with genotyping (HPV16/18 or HPV16/18/31/33/45/52/58) for hrHPV-positive borderlineormilddyskaryosis (BMD)ornormal cytology,usingdata from a population-based hrHPV-based screening trial with 5-year interval (POBASCAM). We considered colposcopy referral at baseline, after 6-month repeat cytology and after 5-year hrHPV testing. Performance was evaluated by one-round positive and negative predictive value (PPVandNPV) for CIN3+ and by two-roundcolposcopy referral rate. To identify efficient strategies, they were ordered by the one-round colposcopy referral rate. Adjacent strategies were compared by the marginal PPV for detecting one additional CIN3+ (mPPV).Results: The most conservative strategy (repeat cytology after BMD and HPV16/18/31/33/45/52/58-positive normal cytology, next round otherwise) yielded an mPPV of 28%, NPV of 98.2%, and two-round colposcopy referral rate of 47.2%. Adding direct referral after BMD or genotype-positive BMD yielded an mPPV <= 8.2%, NPV >= 98.5% and an increase in colposcopy referral rate of 1.9% to 6.5%. Adding direct referral after HPV16/18-positive normal cytology yielded an mPPV <= 3.5%, NPV >= 99.5% and an increase in colposcopy referral rate of 13.9%.Conclusions: Direct colposcopy referral of women with BMD or normal cytology is unlikely to be efficient, but genotype-guided direct referral after BMD may be considered because the increase in colposcopies is limited.Impact: hrHPV screening programs can become very efficient when immediate colposcopy referral is limited to women at highest CIN3+ risk. See related In the Spotlight, p. 979Impact: hrHPV screening programs can become very efficient when immediate colposcopy referral is limited to women at highest CIN3+ risk. See related In the Spotlight, p. 979
引用
收藏
页码:1037 / 1045
页数:9
相关论文
共 50 条
  • [31] Prevalence and determinants of cervical cancer screening with a combination of cytology and human papillomavirus testing
    Domgue, Joel Fokom
    Cunningham, Sonia A.
    Yu, Robert K.
    Shete, Sanjay
    ANNALS OF EPIDEMIOLOGY, 2019, 36 : 40 - 47
  • [32] HPV-negative CIN3 and cervical cancer in Switzerland: any evidence of impact on screening policies?
    Pierre, Vassilakos
    Tran Phuong Lien
    Roland, Sahli
    Nicola, Low
    Patrick, Petignat
    SWISS MEDICAL WEEKLY, 2017, 147
  • [33] Human papillomavirus infection and the risk of cervical cancer in Japan
    Matsumoto, Koji
    Yoshikawa, Hiroyuki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2013, 39 (01) : 7 - 17
  • [34] Detection of high-risk human papillomavirus RNA in urine for cervical cancer screening with HPV 16 & 18/45 genotyping
    Padhy, Radha Rani
    Davidov, Adi
    Madrigal, Louise
    Alcide, Gina
    Spahiu, Almir
    HELIYON, 2020, 6 (04)
  • [35] Utility of Human Papillomavirus Testing for Cervical Cancer Screening in Korea
    Kim, Mee-seon
    Lee, Eun Hee
    Park, Moon-il
    Lee, Jae Seok
    Kim, Kisu
    Roh, Mee Sook
    Lee, Hyoun Wook
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (05)
  • [36] Implementation of human papillomavirus primary screening for cervical cancer in BC
    Gentile, Laura
    Smith, Laurie W.
    Smith, Brenda
    Ogilvie, Gina
    Proctor, Lily
    BRITISH COLUMBIA MEDICAL JOURNAL, 2024, 66 (10): : 375 - 380
  • [37] Practice Patterns in Cervical Cancer Screening and Human Papillomavirus Testing
    Tatsas, Amanda D.
    Phelan, Darcy F.
    Gravitt, Patti E.
    Boitnott, John K.
    Clark, Douglas P.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (02) : 223 - 229
  • [38] Cervical Cancer Screening With Human Papillomavirus DNA and Cytology in Japan
    Sasaki, Yuri
    Iwanari, Osamu
    Arakawa, Ichiro
    Moriya, Takuya
    Mikami, Yoshiki
    Iihara, Kuniko
    Konno, Ryo
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (03) : 523 - 529
  • [39] Stratifying HPV-positive women for CIN3+risk after one and two rounds of HPV-based screening
    Veldhuijzen, Nienke J.
    Polman, Nicole J.
    Snijders, Peter J. F.
    Meijer, Chris J. L. M.
    Berkhof, Johannes
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (08) : 1551 - 1560
  • [40] Primary Screening for Cervical Cancer Based on High-Risk Human Papillomavirus (HPV) Detection and HPV 16 and HPV 18 Genotyping, in Comparison to Cytology
    Agorastos, Theodoros
    Chatzistamatiou, Kimon
    Katsamagkas, Taxiarchis
    Koliopoulos, George
    Daponte, Alexandros
    Constantinidis, Theocharis
    Constantinidis, Theodoros C.
    PLOS ONE, 2015, 10 (03):